Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S (ASND)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/16/2017 11/17/2017 11/20/2017 11/21/2017 11/22/2017 Date
36.75(c) 36.94(c) 36.13(c) 36.49(c) 37.11(c) Last
131 351 366 399 157 101 62 468 301 271 Volume
+4.91% +0.52% -2.19% +1.00% +1.70% Change
More quotes
Financials (€)
Sales 2017 1,73 M
EBIT 2017 -108 M
Net income 2017 -119 M
Finance 2017 178 M
Yield 2017 -
Sales 2018 2,06 M
EBIT 2018 -113 M
Net income 2018 -118 M
Finance 2018 232 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 556x
EV / Sales2018 442x
Capitalization 1 142 M
More Financials
Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates.Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies to address markets with unmet medical needs.The company was founded by Jan Møller Mikkelsen in... 
More about the company
Surperformance© ratings of Ascendis Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ASCENDIS PHARMA A/S
11/23 ASCENDIS PHARMA A/S : AS Announces Participation in Evercore ISI 2017 Biopharma ..
11/21 Ascendis Pharma A/S Announces Participation in Evercore ISI 2017 Biopharma Ca..
11/21 ASCENDIS PHARMA A/S : AS Reports Third Quarter 2017 Financial Results
11/16 Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results
11/16 ASCENDIS PHARMA A/S : Sponsored ADR to Host Earnings Call
11/02 Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference..
11/02 ASCENDIS PHARMA A/S : AS Announces Participation in Two Upcoming Investor Confer..
10/31 Ascendis Pharma A/S Announces Participation in Two Upcoming Investor Conferen..
09/29 ASCENDIS PHARMA A/S : Announces Pricing of Public Offering of ADSs
09/28 ASCENDIS PHARMA A/S : Announces Proposed Public Offering of ADSs
More news
Sector news : Bio Therapeutic Drugs
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/22 After Hours Gainers / Losers
11/20 YOUR DAILY PHARMA SCOOP : Geron's Fate, Celldex Commences Mid-Stage Study, Novar..
11/16 Ascendis Pharma's (ASND) CEO Jan Moller Mikkelsen on Q3 2017 Results - Earnin..
11/16 Ascendis Pharma  reports Q3 results
11/15 Notable earnings after Thursday?s close
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | ASND | US04351P1012 | 4-Traders
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 41,7 €
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, Chief Executive Officer & Director
Mark Peter Brennan Executive Chairman
Neil T. Ringdahl Chief Operating Officer
Scott T. Smith Chief Financial Officer & Senior Vice President
Harald Rau Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S83.35%1 353
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS4.73%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731